-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, BnpV0EJIYO83M9FRYWde98sMuEUeNaGr1Z+GKFAqfj9uUcFR5FWPKVR1/ZvzQ8mh qxScRDyPmAEVM370Zt9ftQ== 0001005794-03-000019.txt : 20030121 0001005794-03-000019.hdr.sgml : 20030120 20030121133555 ACCESSION NUMBER: 0001005794-03-000019 CONFORMED SUBMISSION TYPE: SC 13D/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20030121 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: GREGORY JOHN M CENTRAL INDEX KEY: 0001200376 FILING VALUES: FORM TYPE: SC 13D/A BUSINESS ADDRESS: STREET 1: 340 EDGEMONT AVE STREET 2: SUITE 500 CITY: BRISTOL STATE: TN ZIP: 37620 BUSINESS PHONE: 4239897211 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: CELLEGY PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000887247 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 820429727 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-45279 FILM NUMBER: 03519251 BUSINESS ADDRESS: STREET 1: 349 OYSTER POINT BLVD. STREET 2: SUITE 200 CITY: SO. SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 6506262200 MAIL ADDRESS: STREET 1: 349 OYSTER POINT BLVD. STREET 2: SUITE 200 CITY: SO. SAN FRANCISCO STATE: CA ZIP: 94080 SC 13D/A 1 s13da011303.txt STATEMENT OF BENEFICIAL OWNERSHIP UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES AND EXCHANGE ACT OF 1934 (Amendment No. 4)* CELLEGY PHARMACEUTICALS, INC. - -------------------------------------------------------------------------------- (Name of Subject Company) Common Stock, no par value - -------------------------------------------------------------------------------- (Title of Class Of Securities) 15115L 10 3 - -------------------------------------------------------------------------------- (CUSIP Number) Linda Crouch-McCreadie, Esq. Baker, Donelson, Bearman & Caldwell 207 Mockingbird Lane, Suite 300 Johnson City, Tennessee 37602 (423) 928-0181 - -------------------------------------------------------------------------------- (Name, Address and Telephone Numbers of Person Authorized to Receive Notices and Communications) January 13, 2003 - -------------------------------------------------------------------------------- (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this Schedule because of ss.ss.240.13d-1(e), 240.13d- 1(f) or 240.13d-1(g), check the following box [ ]. Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See ss.240.13d-7 for other parties to whom copies are to be sent. * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). - -------------------------------------------------------------------------------- CUSIP No. 15115L 10 3 Page 2 - -------------------------------------------------------------------------------- 1. Names of Reporting Persons. S.S. or John M. Gregory I.R.S. Identification Nos. of Above Persons - -------------------------------------------------------------------------------- 2. Check the Appropriate Box if a Member (a) of a Group (See Instructions) (b) X - -------------------------------------------------------------------------------- 3. SEC Use Only - -------------------------------------------------------------------------------- 4. Source of Funds (See Instructions) PF - -------------------------------------------------------------------------------- 5. Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e) - -------------------------------------------------------------------------------- 6. Citizenship or Place of Organization United States of America - -------------------------------------------------------------------------------- Number of Shares 7. Sole Voting Power 0 Beneficially ------------------------------------------------------ Owned by Each 8. Shared Voting 4,884,330 Reporting Person Power with ------------------------------------------------------ 9. Sole Dispositive 0 Power ------------------------------------------------------ 10. Shared Dispositive 4,884,330 Power - -------------------------------------------------------------------------------- 11. Aggregate Amount Beneficially Owned 4,884,330 by Each Reporting Person - -------------------------------------------------------------------------------- 12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) - -------------------------------------------------------------------------------- 13. Percent of Class Represented by Amount 25.0% in Row (11) - -------------------------------------------------------------------------------- 14. Type of Reporting Person (See IN Instructions) - -------------------------------------------------------------------------------- - -------------------------------------------------------------------------------- CUSIP No. 15115L 10 3 Page 3 - -------------------------------------------------------------------------------- 1. Names of Reporting Persons. S.S. or Joan P. Gregory I.R.S. Identification Nos. of Above Persons - -------------------------------------------------------------------------------- 2. Check the Appropriate Box if a Member (a) of a Group (See Instructions) (b) X - -------------------------------------------------------------------------------- 3. SEC Use Only - -------------------------------------------------------------------------------- 4. Source of Funds (See Instructions) PF - -------------------------------------------------------------------------------- 5. Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e) - -------------------------------------------------------------------------------- 6. Citizenship or Place of Organization United States of America - -------------------------------------------------------------------------------- Number of Shares 7. Sole Voting Power 0 Beneficially ------------------------------------------------------ Owned by Each 8. Shared Voting 4,884,330 Reporting Person Power with ------------------------------------------------------ 9. Sole Dispositive 0 Power ------------------------------------------------------ 10. Shared Dispositive 4,884,330 Power - -------------------------------------------------------------------------------- 11. Aggregate Amount Beneficially Owned by Each Reporting Person 4,884,330 - -------------------------------------------------------------------------------- 12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions) - -------------------------------------------------------------------------------- 13. Percent of Class Represented by Amount 25.0% in Row (11) - -------------------------------------------------------------------------------- 14. Type of Reporting Person (See IN Instructions) - -------------------------------------------------------------------------------- This Amendment No. 4 to the Schedule 13D relating to shares of Common Stock, no par value (the "Common Stock") of Cellegy Pharmaceuticals, Inc. (the "Issuer"), is being filed by John M. Gregory and Joan P. Gregory (collectively, the "Reporting Persons") to report an increase in beneficial ownership of greater than 1% of the Common Stock of the Issuer and to otherwise amend Items 3 and 5 of the Schedule 13D filed on October 22, 2002. Amendment No. 1 to the Schedule 13D relating to shares of Common Stock of the Issuer was filed by the Reporting Persons on October 29, 2002 to report an increase in beneficial ownership of greater than 1% of the Common Stock of the Issuer and to otherwise amend Items 3 and 5 of the Schedule 13D. Amendment No. 2 to the Schedule 13D relating to shares of Common Stock of the Issuer was filed by the Reporting Persons on November 13, 2002 to report an increase in beneficial ownership of greater than 1% of the Common Stock of the Issuer and to otherwise amend Items 3, 5 and 6 of the Schedule 13D. Amendment No. 3 to the Schedule 13D relating to shares of Common Stock of the Issuer was filed by the Reporting Persons on December 23, 2002 to report an increase in beneficial ownership of greater than 1% of the Common Stock of the Issuer and to otherwise amend Items 3 and 5 of the Schedule 13D. Item 1. Security and Issuer. ------------------- The title and class of equity securities to which this statement relates is the Common Stock, no par value (the "Common Stock"), of Cellegy Pharmaceuticals, Inc. (the "Issuer"). The Issuer's principal executive offices are located at 349 Oyster Point Boulevard, Suite 200, South San Francisco, California 94080. Item 2. Identity and Background. ----------------------- (a) John M. Gregory and Joan P. Gregory, husband and wife (collectively, the "Reporting Persons") (b) The address for the Reporting Persons is: c/o SJ Strategic Investments LLC 340 Edgemont Avenue, Suite 500 Bristol, TN 37620. (c) John M. Gregory is the Managing Partner of SJ Strategic Investments LLC. Joan P. Gregory is a homemaker and is not presently employed in any other capacity. (d)and(e) Neither of the Reporting Persons has, during the last five years, (i) been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or (ii) been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting activities subject to, federal or state securities laws or finding any violation of such laws. (f) The Reporting Persons are citizens of the United States of America. Item 3. Source and Amount of Funds or Other Consideration. ------------------------------------------------- All securities acquired by the Reporting Persons were purchased with the personal funds of the Reporting Persons. The aggregate purchase price of the Common Stock was approximately $13,645,900 including $5,500,000 paid to the Issuer for shares of Common Stock purchased by the Reporting Persons pursuant to that certain Common Stock Purchase Agreement by and between the Issuer and John M. Gregory, dated November 6, 2002 (the "Stock Purchase Agreement"). Item 4. Purpose of Transaction. ---------------------- Each of the Reporting Persons has acquired the shares of Common Stock for investment purposes and may acquire additional shares, or dispose of some or all of the shares of Common Stock, from time to time, depending upon price and market conditions, evaluation of alternative investments and other factors. The Reporting Persons intend to review on a continuing basis their investment in the Common Stock, the Issuer's business affairs and financial condition, as well as conditions in the securities markets and general economic and industry conditions. 4 of 7 Neither of the Reporting Persons has any plan or proposal which relates to or which would result in: (a) An extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer; (b) The sale or transfer of a material amount of assets of the Issuer; (c) Any change in the present Board of Directors or management of the Issuer, including any plans or proposals to change the number or terms of Directors or to fill any existing vacancies on the Board; (d) Any material change in the present capitalization or dividend policy of the Issuer; (e) Any other material change in the Issuer's business or corporate structure; (f) Changes in the Issuer's Articles of Incorporation, Bylaws or other actions which may impede the acquisition or control of the Issuer by any person; (g) Causing a class of securities of the Issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted in an interdealer quotation system of a registered national securities association; (h) A class of equity securities of the Issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Exchange Act; or (i) Any action similar to any of those enumerated above. Item 5. Interest in Securities of Issuer. -------------------------------- (a) The calculations in this Item are based upon 19,504,976 shares of Common Stock issued and outstanding as of November 8, 2002 (based on disclosures made by the Issuer in its Quarterly Report on Form 10-Q filed on November 15, 2002). As of the date hereof, the Reporting Persons jointly beneficially owned 4,884,330 shares or 25.0% of the outstanding shares of Common Stock of the Issuer. The foregoing calculation is made pursuant to Rule 13d-3 promulgated under the Act. (b) The Reporting Persons share the power to vote or direct the vote of 4,884,330 shares and share the power to dispose or direct the disposition of 4,884,330 shares. 5 of 7 (c) During the 60 day period ended as of the date hereof, the Reporting Persons have engaged in the following transactions, with all purchases having been made for cash: Transaction Date No. of Shares Price Per Share ----------- ---- ------------- --------------- Purchase 12/17/02 28,900 $ 3.75 Purchase 12/18/02 36,500 $ 3.96 Purchase 12/19/02 123,700 $ 4.13 Purchase 12/20/02 39,700 $ 4.15 Purchase 01/06/03 16,000 $ 4.36 Purchase 01/07/03 89,500 $ 4.90 Purchase 01/10/03 62,980 $ 4.96 Purchase 01/13/03 70,700 $ 5.13 Purchase 01/14/03 96,250 $ 5.28 Purchase 01/15/03 6,927 $ 5.30 Purchase 01/16/03 202,467 $ 5.52 Purchase 01/17/03 33,806 $ 5.44 Except for the puchase of 2,200,000 shares of Common Stock on November 6, 2002, each of the transactions listed above was an open market transaction. The purchase on November 6, 2002 was made pursuant to the Stock Purchase Agreement. (d) The Reporting Persons affirm that no other person has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of the Issuer's Common Stock beneficially owned by the Reporting Persons. (e) Not Applicable. Item 6. Contracts, Arrangements, Understandings or Relationships With Respect ---------------------------------------------------------------------- to Securities of the Issuer. ---------------------------- Other than the Stock Purchase Agreement, the Reporting Persons do not have any contract, arrangement, understandings or relationships with respect to securities of the Issuer. Pursuant to the Stock Purchase Agreement, the Issuer has agreed to file an initial shelf registration statement (the "Shelf Registration Statement") with the Securities and Exchange Commission (the "Commission") within 45 days of the closing of the transaction and use its best efforts to have the Shelf Registration Statement declared effective as soon as practicable thereafter (but in any event within 90 days after filing). The Issuer has agreed to use its best efforts to keep the Shelf Registration Statement effective for the period set forth in the Stock Purchase Agreement. Item 7. Material to be Filed as Exhibits. --------------------------------- Exhibit Description ------- ----------- 1 Joint Filing Agreement 2* Common Stock Purchase Agreement by and between Cellegy Pharmaceuticals, Inc. and John M. Gregory, dated November 6, 2002. - ---------------------- *Previously filed with the Securities and Exchange Commission as an exhibit to Amendment No. 2 to the Schedule 13D filed by the Reporting Persons on November 13, 2002 and incorporated herein by reference. 6 of 7 SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: January 21, 2003 /s/ John M. Gregory -------------------------------------- John M. Gregory /s/ Joan P. Gregory -------------------------------------- Joan P. Gregory 7 of 7 EXHIBIT INDEX Exhibit Description ------- ----------- 1 Joint Filing Agreement 2* Common Stock Purchase Agreement by and between Cellegy Pharmaceuticals, Inc. and John M. Gregory, dated November 6, 2002. - ----------------------- *Previously filed with the Securities and Exchange Commission as an exhibit to Amendment No. 2 to the Schedule 13D filed by the Reporting Persons on November 13, 2002 and incorporated herein by reference. EXHIBIT 1 JOINT FILING AGREEMENT John M. Gregory and Joan P. Gregory (the "Filing Persons"), hereby agree to file jointly a Schedule 13D and any amendments thereto relating to the aggregate ownership by each of the Filing Persons of any voting equity security of a class which is registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended, as required by Rule 13d-1 and Rule 13d-2 promulgated under the Securities Exchange Act of 1934. Each of the Filing Persons agrees that the information set forth in such Schedule 13D and any amendments thereto with respect to such Filing Person will be true, complete and correct as of the date of such Schedule 13D or such amendment, to the best of such Filing Person's knowledge and belief, after reasonable inquiry. Each of the Filing Persons makes no representation as to the accuracy or adequacy of the information set forth in the Schedule 13D or any amendments thereto with respect to any other Filing Person. Each of the Filing Persons shall promptly notify the other Filing Persons if any of the information set forth in the Schedule 13D or any amendments thereto shall become inaccurate in any material respect or if said person learns of information that would require an amendment to the Schedule 13D. IN WITNESS WHEREOF, the undersigned have set their hands this 21st day of January, 2003. /s/ John M. Gregory ------------------------------------ John M. Gregory /s/ Joan P. Gregory ------------------------------------ Joan P. Gregory -----END PRIVACY-ENHANCED MESSAGE-----